Abstract

7542Background: Forodesine, a potent purine nucleoside phosphorylase inhibitor, induces apoptosis mainly in T cells. Forodesine at relatively low dose was feasible but the response rate was not suf...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
Shinichi Makita ... Akiko Miyagi Maeshima
OncoTargets and Therapy | VOL. 11
Shinichi Makita, et. al.Shinichi Makita ... Akiko Miyagi Maeshima
01 Apr 2018
Updated Report of a Phase I/II Multicenter Study of Forodesine, a Purine Nucleoside Phosphorylase Inhibitor, in Japanese Patients with Relapsed Peripheral T-Cell Lymphoma
...
Blood | VOL. 130
, et. al. ...
25 Jun 2021
Phase I Study of Forodesine (BCX1777), An Oral PNP Inhibitor In Patients with Relapsed or Refractory T/NK Malignancies.
Kunihiro Tsukasaki ... Kensei Tobinai
Blood | VOL. 116
Kunihiro Tsukasaki, et. al.Kunihiro Tsukasaki ... Kensei Tobinai
19 Nov 2010
Preliminary report on 8-amino-9-(2-thienylmethyl)guanine (PD 119,229), a novel and potent purine nucleoside phosphorylase inhibitor.
R B Gilbertsen ... J C Sircar
Inflammation research : official journal of the European Histamine Research Society ... [et al.] | VOL. 21
R B Gilbertsen, et. al.R B Gilbertsen ... J C Sircar
01 Aug 1987
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Erratum: Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG).
-
Journal of Clinical Oncology | VOL. -
--
03 Jul 2024
Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial.
Sabashini K Ramchand ... Mathis Grossmann
Journal of Clinical Oncology | VOL. -
Sabashini K Ramchand, et. al.Sabashini K Ramchand ... Mathis Grossmann
02 Jul 2024
Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced/Metastatic Genitourinary Tumors.
Andrea B Apolo ... Amir Mortazavi
Journal of Clinical Oncology | VOL. -
Andrea B Apolo, et. al.Andrea B Apolo ... Amir Mortazavi
02 Jul 2024
Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma.
Paul A Meyers ... Joseph A Ludwig
Journal of Clinical Oncology | VOL. -
Paul A Meyers, et. al.Paul A Meyers ... Joseph A Ludwig
02 Jul 2024
View more papers